SciBase receives additional order from Castle Biosciences, advancing the collaboration
SciBase has received an additional order from Castle Biosciences valued at approximately $0.6 million to accelerate an ongoing clinical study and prepare for a second study. The order includes the portable Nevisense Go pen device and electrodes, with deliveries expected to begin in Q4 2026.
Key figures
- Study acceleration
- Yes
- Second study preparation
- Yes
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.